Mannatech, Incorporated has reported its financial results for the third quarter of 2026, revealing significant challenges in its operations. The company, which specializes in medicinal chemicals and botanical products, reported a notable decline in net sales and gross profit margins, raising concerns about its future performance.

On November 12, 2026, Mannatech issued a press release detailing its financial results for the quarter ended September 30, 2026. The report is critical as it reflects the company’s current standing in a competitive industry that is increasingly focused on health and wellness products.

Background

Mannatech Inc. is a Texas-based company listed on the Nasdaq under the ticker MTEX. It operates within the SIC classification of 2833, which encompasses medicinal chemicals and botanical products. The company has been recognized for its commitment to transforming lives through health and wellness solutions. Recent filings indicate that Mannatech is a smaller reporting company, which may influence its operational strategies and financial disclosures.

What the Filing Says

According to the recent filing, Mannatech reported net sales of $24.9 million for the third quarter, a decrease of $4.3 million compared to the same period in 2025. The company noted that on a constant dollar basis, net sales also decreased by 14.6%. Additionally, gross profit as a percentage of net sales fell to 74.7%, down from 76.4% in the previous year.

The filing further revealed that selling and administrative expenses decreased by $0.4 million, but as a percentage of net sales, these expenses increased to 35.0%, compared to 31.1% in the same period last year. Income from operations was reported at $0.3 million, a significant drop from $2.0 million in the same quarter of 2025.

Impact

The decline in net sales and profit margins may affect various stakeholders, including investors, employees, and customers. Investors may be concerned about the company's ability to maintain profitability in a competitive market. Employees could face uncertainty regarding job security and future growth opportunities, while customers may experience changes in product offerings or pricing strategies.

What's Next

The filing does not specify what happens next for Mannatech following these results. However, the company may need to implement strategic changes to address the declining sales and profitability. This could involve revising marketing strategies, enhancing product offerings, or exploring new markets.

As the medicinal chemicals and botanical products industry continues to evolve, Mannatech's ability to adapt will be crucial for its long-term success. The company’s next steps will be closely monitored by industry analysts and competitors alike, as they navigate similar market challenges.